Irinotecan Aurobindo (Irinotecan Hydrochloride Trihydrate)

Irinotecan Aurobindo is a Topoisomerase I inhibitor used in colorectal cancer treatment pathways.

• Metastatic colorectal cancer: used in combination regimens to improve overall survival in patients with advanced disease.
• First‑line colorectal cancer therapy: administered with fluorouracil and leucovorin as part of the FOLFIRI regimen to treat newly diagnosed metastatic cases.
• Second‑line colorectal cancer therapy: employed after progression on oxaliplatin‑based regimens to provide an alternative cytotoxic option.

• Irinotecan is converted intracellularly to its active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This binding prevents the re‑ligation of single‑strand DNA breaks generated during replication, leading to accumulation of DNA damage, replication fork collapse, and ultimately tumor cell death.

Irinotecan therapy is associated with a range of adverse reactions that require monitoring.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Diarrhea: often severe and may require antidiarrheal treatment.
• Nausea and vomiting: typical chemotherapy‑related gastrointestinal upset.
• Fatigue: generalized tiredness affecting daily activities.
• Alopecia: temporary hair loss during treatment.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Severe colitis: intense inflammation of the colon that may be life‑threatening.
• Hepatic toxicity: elevated liver enzymes or bilirubin indicating liver injury.
• Allergic reactions: rash, itching, or anaphylaxis in susceptible individuals.
• Infusion‑related reactions: hypotension, dyspnea, or chest discomfort during administration.

Prior to initiating Irinotecan Aurobindo, clinicians should assess patient risk factors and implement monitoring strategies.

• Monitor blood counts: perform regular CBC to detect neutropenia and guide dose adjustments.
• Assess liver function: check hepatic enzymes before and during therapy to avoid accumulation of SN‑38.
• Maintain hydration: ensure adequate fluid intake to mitigate severe diarrhea.
• Avoid concurrent myelosuppressive agents: limit additive bone‑marrow suppression when possible.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure and toxicity.
• Concurrent myelosuppressive chemotherapy: exacerbate bone‑marrow suppression and infection risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): reduce irinotecan effectiveness by lowering plasma levels.
• Drugs affecting bilirubin transport (e.g., atazanavir): may raise SN‑38 concentrations and toxicity.
• Warfarin: potential alteration of INR, requiring closer coagulation monitoring.
• Antacids containing magnesium or aluminum: may affect gastrointestinal absorption of oral formulations, though less relevant for IV use.